NCT00351728

Brief Summary

Patients diagnosed with ocular melanoma consent to participate in the study. Combined PET/CT scans of the whole body are performed at baseline, three months later, and six months after that for a total of three combined scans in the first year. Subsequently, these combined scans will be performed at 6-monthly intervals for a total of two combined scans per year.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
174

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2006

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2006

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 12, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 13, 2006

Completed
6.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2012

Completed
Last Updated

July 7, 2016

Status Verified

July 1, 2016

Enrollment Period

6.2 years

First QC Date

July 12, 2006

Last Update Submit

July 5, 2016

Conditions

Ocular MelanomaChoroidal MelanomaUveal Melanoma

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

choroidal melanoma patients

You may qualify if:

  • Patients with a diagnosis of ocular melanoma (a pigmented malignant tumor) involving the choroid and/or ciliary body (the blood vessel layer in the back of the eye and/or the part of the eye behind the iris).
  • Patients 18 years of age or older.
  • Patients able to give informed consent.

You may not qualify if:

  • Patients who refuse to participate in the study.
  • Patients who are unable to cooperate with or cannot undergo PET/CT scanning.
  • Patients who will be moving out of the area of UCLA during the ten years of this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jules Stein Eye Institute

Los Angeles, California, 90095-7000, United States

Location

MeSH Terms

Conditions

Uveal Melanoma

Condition Hierarchy (Ancestors)

MelanomaNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasUveal NeoplasmsEye NeoplasmsNeoplasms by SiteEye DiseasesUveal Diseases

Study Officials

  • Tara A McCannel, MD, PhD

    Jules Stein Eye Institute, UCLA

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2006

First Posted

July 13, 2006

Study Start

June 1, 2006

Primary Completion

August 1, 2012

Study Completion

August 1, 2012

Last Updated

July 7, 2016

Record last verified: 2016-07

Locations

US(1)